Items where Author or Editor is "Scheid, C." - Kölner UniversitätsPublikationsServer

Group by: Item Type | Date | No Grouping

Jump to: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2011

Number of items: 74.

2020

Asemissen, A. M., Scheid, C., Leypoldt, L., Schieferdecker, A., Besemer, B., Blau, I. -W., Goerner, M., Ko, Y. -D., Haenel, M., Duerig, J., Staib, P., Salwender, H., Mann, C., Munder, M., Graeven, U., Peceny, R., Lutz, R., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. and Weisel, K. (2020). Mobilization of autologous stem cells under induction therapy with Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone (Isa-KRd) in high risk myeloma patients: First results of the GMMG-CONCEPT trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 94 - 96. BASEL: KARGER. ISSN 2296-5262

Barnert, A., Kunze, A., Scheid, C., Liekweg, A., Hermes-Moll, K. and Jaehde, U. (2020). Extended medication plan for patients with ORal tumortherapy (EMPORT). Int. J. Clin. Phar,., 42 (1). S. 234 - 236. DORDRECHT: SPRINGER. ISSN 2210-7711

Borchmann, P., Juehling, A., Goedel, P., Balke-Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Preussner, L., Zadoyan, G., Hanssens, L., Kaiser, A., Jurk, M., Buerger, I, Schneider, D., Dropulic, B., Overstijns, T., Holtick, U., Scheid, C., Miltenyi, S. and Hallek, M. (2020). Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 56 - 57. BASEL: KARGER. ISSN 2296-5262

Piechotta, V, John, L., Jung, J., Graziani, G., Reinhardt, H., Holtick, U., Semrau, R., Trog, D., Voelker, L. A., Herling, M., Fend, F., Harder, L., Weinhold, N., Kriegsmann, K., Merz, M., Delorme, S., Derlin, T., Raab, M. S., Goede, V, Schubert, M., Hohloch, K., Senf, B., Simon, S. T., Baumann, W., Fetscher, S., Schinke, M., Holtkamp, U., Einsele, H., Engelhardt, M., Goldschmidt, H., Scheid, C. and Skoetz, N. (2020). Interdisciplinary guideline on diagnosis, therapy, and follow-up of adult patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Oncol. Res. Treat., 43 (SUPPL 4). S. 96 - 97. BASEL: KARGER. ISSN 2296-5262

Richardson, T., Herling, M., Cruz-Aguilar, M. R., Frenzel, L. P., Hallek, M., Scheid, C. and Holtick, U. (2020). High-dose melphalan and autologous stem cell transplantation in elderly patients >= 70 years is safe and effective - A retrospective analysis. Oncol. Res. Treat., 43 (SUPPL 4). S. 107 - 108. BASEL: KARGER. ISSN 2296-5262

Scheid, C., Basic, E., Sellner, L., Ratsch, B. and Blau, W., I (2020). Changes in the treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from a large German claims database. Oncol. Res. Treat., 43 (SUPPL 4). S. 105 - 107. BASEL: KARGER. ISSN 2296-5262

Sockel, K., Frank, S., Neu, A., Ditschkowski, M., Hilgendorf, I., Goeckenjan, M., Stoelzel, F., Middeke, J. M., Kroeger, N., Ayuketang, Ayuk F., Eder, M., Bethge, W., Finke, J., Bertz, H., Kobbe, G., Kaufmann, M., Platzbecker, U., Beverungen, D., Schmid, C., von Bonin, M., Heberling, L., Teipel, R., Bug, G., Fraccaroli, A., Tischer, J., Holler, B., Wolff, D., Luft, T., Roesler, W., Schaefer-Eckart, K., Dressler, S., Scheid, C., Holtick, U., Klein, S., Blau, I. -W., Burchert, A., Wulf, G., Hasenkamp, J., Kaun, S., Wittke, C., Wortmann, F., Bornhaeuser, M. and Schetelig, J. (2020). Evaluation of pregnancies after allogeneic stem cell transplantation during the last 15years in Germany. Oncol. Res. Treat., 43 (SUPPL 4). S. 240 - 241. BASEL: KARGER. ISSN 2296-5262

Steven, P., Faust, C., Holtick, U., Scheid, C., Tahmaz, V., Stern, M. E. and Gehlsen, U. (2020). Adverse environmental conditions are a risk factor for ocular GvHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant., 55 (9). S. 1851 - 1854. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Stroh, J., Seckinger, A., Heider, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K., Scheid, C., Keller, U., Hose, D. and Bassermann, F. (2020). MCT1 as molecularly validated predictive marker for lenalidomide-maintenance therapy in multiple myeloma. Oncol. Res. Treat., 43 (SUPPL 4). S. 95 - 96. BASEL: KARGER. ISSN 2296-5262

Vitinius, F., Scheid, C., Hellmich, M., Bergwelt, M., Scherer, S. and Albus, C. (2020). Psychosocial pre-transplant screening with the transplant evaluation rating scale contributes to prediction of survival after hematopoietic stem cell transplantation. J. Psychosomat. Res., 133. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1879-1360

Vitinius, F., Scherer, S., Scheid, C., von Bergwelt, M., Hellmich, M. and Albus, C. (2020). PSYCHOSOCIAL PRE-TRANSPLANT SCREENING WITH THE TRANSPLANT EVALUATION RATING SCALE CONTRIBUTES TO PREDICTION OF SURVIVAL AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. Transpl. Int., 33. S. 8 - 9. HOBOKEN: WILEY. ISSN 1432-2277

2019

Stein-Thoeringer, C. K., Nichols, K. B., Lazrak, A., Docampo, M. D., Slingerland, A. E., Slingerland, J. B., Clurman, A. G., Armijo, G., Gomes, A. L. C., Shono, Y., Staffas, A., da Silva, M. Burgos, Devlin, S. M., Markey, K. A., Bajic, D., Pinedo, R., Tsakmaklis, A., Littmann, E. R., Pastore, A., Taur, Y., Monette, S., Arcila, M. E., Pickard, A. J., Maloy, M., Wright, R. J., Amoretti, L. A., Fontana, E., Pham, D., Jamal, M. A., Weber, D., Sung, A. D., Hashimoto, D., Scheid, C., Xavier, J. B., Messina, J. A., Romero, K., Lew, M., Bush, A., Bohannon, L., Hayasaka, K., Hasegawa, Y., Vehreschild, M. J. G. T., Cross, J. R., Ponce, D. M., Perales, M. A., Giralt, S. A., Jenq, R. R., Teshima, T., Holler, E., Chao, N. J., Pamer, E. G., Peled, J. U. and van den Brink, M. R. M. (2019). Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science, 366 (6469). S. 1143 - 1191. WASHINGTON: AMER ASSOC ADVANCEMENT SCIENCE. ISSN 1095-9203

2018

Althoff, K., Leitzke, S., Herling, C., Frenzel, L., Schiller, J., Herling, M., Holtick, U., Scheid, C. and Theurich, S. (2018). Metabolic status and immune activation prior conditioning influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. Oncol. Res. Treat., 41. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262

Evers, G., Beelen, D. W., Braess, J., Sauerland, M. C., Kolb, H. J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Krug, U., Mueller-Tidow, C., Schliemann, C., Mikesch, J. -H., Lenz, G., Woermann, B. J., Hiddemann, W., Berdel, W. E. and Stelljes, M. (2018). Allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete remission (CR) in patients with acute myeloid leukemia (AML): Results from the AMLCG1999 trial. Oncol. Res. Treat., 41. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262

Farowski, F., Bueker, V., Vehreschild, J. J., Biehl, L., Cruz-Aguilar, R., Scheid, C., Holtick, U., Jazmati, N., Wisplinghoff, H., Cornely, O. A. and Vehreschild, M. J. G. T. (2018). Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant., 53 (1). S. 52 - 58. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J. and Sonneveld, P. (2018). Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial. Leukemia, 32 (2). S. 383 - 391. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Holtick, U., Herling, M., Theurich, S., Frenzel, L., Herling, C., Schiller, J., Hallek, M. and Scheid, C. (2018). A phase II study to investigate the efficacy of short-term everolimus in addition to post-transplant cyclophosphamide as graft-versus-host-prophylaxis after allogeneic hematopoietic stem cell transplantation (OCTET-EVER). Oncol. Res. Treat., 41. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262

Merz, M., Hielscher, T., Seckinger, A., Jauch, A., Mai, E. K., Bertsch, U., Raab, M. S., Neben, K., Salwender, H., Blau, I. W., Lindemann, H. W., Duerig, J., Scheid, C., Haenel, M., Weisel, K., Delorme, S., Kauczor, H. U., Hose, D., Goldschmidt, H. and Hillengass, J. (2018). MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION IDENTIFIES PATIENTS WITH ADVERSE OUTCOME BUT RESPONSE TO TREATMENT WITHIN THE PROSPECTIVE GMMG MM5 PHASE III TRIAL. Haematologica, 103. S. 11 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Pflug, N., Chakupurakal, G., Theurich, S., Holtick, U., Leitzke, S., Chemnitz, J., Scheid, C., Hallek, M. and von Bergwelt-Baildon, M. (2018). Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience. Oncol. Res. Treat., 41. S. 102 - 103. BASEL: KARGER. ISSN 2296-5262

Scheid, C., Roellig, C., Weisel, K., Salwender, H-J, Gramatzki, M., Edmaier-Schroeger, K., Sy, O. and Goldschmidt, H. (2018). Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM). Oncol. Res. Treat., 41. S. 189 - 190. BASEL: KARGER. ISSN 2296-5262

Weisel, K., Salwender, H., Scheid, C., Zago, M., Besemer, B., Haenel, M., Duerig, J., Munder, M., Lindemann, H. -W, Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Kanz, L. and Goldschmidt, H. (2018). Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma: Final results of the GMMG-PERSPECTIVE trial. Oncol. Res. Treat., 41. S. 133 - 135. BASEL: KARGER. ISSN 2296-5262

2017

Auner, H., Iacobelli, S., Bianchi, G., Knol-Bout, C., Blaise, D., Russell, N., Apperley, J., Pohlreich, D., Browne, P., Kobbe, G., Isaksson, C., Lenhoff, S., Scheid, C., Chevallier, P., Jantunen, E., Anagnostopoulos, A., Yakoub-Agha, I., Tanase, A., Schaap, N., Wiktor-Jedrzejczak, W., Mayer, J., Schoenland, S., Morris, C., Garderet, L. and Kroeger, N. (2017). The impact of melphalan dosage on outcomes of autologous haematopoietic cell transplantation for multiple myeloma: Results from the EBMT collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. Bone Marrow Transplant., 52. S. S473 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Busani, A., Stoermer, M., Gathof, B. and Scheid, C. (2017). Transfusion requirement after hematopoietic stem cell transplantation. Transfus. Med. Hemother., 44. S. 81 - 82. BASEL: KARGER. ISSN 1660-3818

Dreger, P., Boumendil, A., Koster, L., Scheid, C., Passweg, J., Veelken, H., Cahn, Y., Collin, M., Wilson, K., Bazarbachi, A., Mayer, J., Corradini, P., Hunault-Berger, M., Parody Porras, R., Gribben, J., Bittenbring, J., Wolff, D., Charbonnier, A., Cambier, N., Montoto, S., Kroeger, N. and Schetelig, J. (2017). No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties. Bone Marrow Transplant., 52. S. S424 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S. and Schetelig, J. (2017). Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant., 52. S. S99 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Glossmann, J-P, Scheid, C., Engelhardt, M., Goldschmidt, H., Einsele, H., Starbatty, B., Bischoff, M., Follmann, M. and Skoetz, N. (2017). NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE OF MULTIPLE MYELOMA PATIENTS. Haematologica, 102. S. 512 - 514. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H-J, Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Burchert, A., Voskanyan, A., Rinaldetti, S., Goebeler, M., Dengler, J., Ho, A., Falge, C., Kanz, L., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Fuchs, R., Scheid, C., Haenel, M., Koehne, C-H, Bruemmendorf, H., Lindemann, H-W, Berdel, W. E., Staib, P., Balleisen, L., Brossart, P., Schenk, M., Zankovich, R., Geer, T., Hertenstein, B., Bildat, S., Hochhaus, A. and Hasford, J. (2017). ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV. Haematologica, 102. S. 151 - 153. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Kraemer, I., Stilgenbauer, S., Dietrich, S., Boettcher, S., Bunjes, D. W., Zeis, M., Stadler, M., Bittenbring, J. T., Uharek, L., Scheid, C., Hegenbart, U., Ho, A., Anthony, D., Hallek, M., Kneba, M., Schmitz, N., Doehner, H. and Dreger, P. (2017). Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial. Bone Marrow Transplant., 52. S. S424 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Lawless, S., Morris, C., Iacobelli, S., Bianchi, G., Bosman, P., Blaise, D., Remenyi, P., Russell, N. H., Mayer, J., Apperley, J., Ljungman, P., Kobbe, G., Schaap, N., Isaksson, C., Lenhoff, S., Wiktor-Jedrzejczak, W., Chevallier, P., Wilson, K. M. O., Muniz, S. G., Scheid, C., Schoenland, S., Garderet, L. and Kroeger, N. (2017). Outcome of the rare myeloma subtypes: An analysis of the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) data. Bone Marrow Transplant., 52. S. S67 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Pfreundschuh, M., Duehrsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Hose, D., Merz, M., Breitkreutz, I., Jauch, A., Martin, H., Lindemann, H. -W., Scheid, C., Weisel, K. C., Blau, I. W. and Goldschmidt, H. (2017). Prediction of early overall and infection-related mortality during induction therapy in transplant-eligible multiple myeloma - a pooled analysis from three GMMG phase III trials. Oncol. Res. Treat., 40. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262

Scheid, C., de Wreede, L., van Biezen, A., Koenecke, C., Gohring, G., Volin, L., Maertens, J., Finke, J., Passweg, J., Beelen, D., Cornelissen, J. J., Itaelae-Remes, M., Chevallier, P., Russell, N., Petersen, E., Milpied, N., Espiga, C. Richard, Peniket, A., Sierra, J., Mufti, G., Crawley, C., Veelken, J. H., Ljungman, P., Cahn, J. Y., Alessandrino, E. P., de Witte, T., Robin, M. and Kroeger, N. (2017). Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. Bone Marrow Transplant., 52 (11). S. 1519 - 1526. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von, Bubnoff N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). Pomalidomide plus ruxolitinib in myelofibrosis: Updated results from the MPNSG-0212 trial. Oncol. Res. Treat., 40. S. 149 - 150. BASEL: KARGER. ISSN 2296-5262

Stegelmann, F., Griesshammer, M., Koschmieder, S., Reiter, A., Hochhaus, A., Heidel, F., von Bubnoff, N., Kindler, T., Hebart, H., Bangerter, M., Wolleschak, D., Moehle, R., Scheid, C., Reim, R., Sutter, U., Vetter, K., Doehner, H. and Doehner, K. (2017). COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110). Haematologica, 102. S. 280 - 281. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2016

Gratwohl, A., Pfirrmann, M., Zander, A., Kroger, N., Beelen, D., Novotny, J., Nerl, C., Scheid, C., Spiekermann, K., Mayer, J., Sayer, H. G., Falge, C., Bunjes, D., Doehner, H., Ganser, A., Schmidt-Wolf, I., Schwerdtfeger, R., Baurmann, H., Kuse, R., Schmitz, N., Wehmeier, A., Fischer, J. Th, Ho, A. D., Wilhelm, M., Goebeler, M-E, Lindemann, H. W., Bormann, M., Hertenstein, B., Schlimok, G., Baerlocher, G. M., Aul, C., Pfreundschuh, M., Fabian, M., Staib, P., Edinger, M., Schatz, M., Fauser, A., Arnold, R., Kindler, T., Wulf, G., Rosselet, A., Hellmann, A., Schaefer, E., Pruemmer, O., Schenk, M., Hasford, J., Heimpel, H., Hossfeld, D. K., Kolb, H-J, Buesche, G., Haferlach, C., Schnittger, S., Mueller, M. C., Reiter, A., Berger, U., Saussele, S., Hochhaus, A. and Hehlmann, R. (2016). Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 30 (3). S. 562 - 570. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Holtick, U., Herling, M., Pflug, N., Chakupurakal, G., Leitzke, S., Wolf, D., Hallek, M., Scheid, C. and Chemnitz, J. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol containing treosulfan in an elderly population with AML. Bone Marrow Transplant., 51. S. S442 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Posdzich, P., Herling, M., Chemnitz, J., Leitzke, S., Di Christanziano, V, Hoeller, K., Kaiser, R., Scheid, C. and Holtick, U. (2016). BKV disease during the first 100 days after allogeneic hematopoietic stem cell transplantation - results of a screening program and retrospective analysis. Oncol. Res. Treat., 39. S. 80 - 81. BASEL: KARGER. ISSN 2296-5262

Scheid, C., Chemnitz, J., Herling, M., Pflug, N., Theurich, S., Burst, A., Leitzke, S., von Bergwelt-Baildon, M., Hallek, M. and Holtick, U. (2016). A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS FOR HODGKIN'S LYMPHOMA? Haematologica, 101. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Scheid, C., Engelhardt, M., Goldschmidt, H., Einsele, H., Starbatty, B., Bischoff, M., Glossmann, J-P and Skoetz, N. (2016). Standard Operating Procedures (SOPs) of centers of excellence for the diagnosis, treatment and follow-up of multiple myeloma patients: similarities and differences. Oncol. Res. Treat., 39. S. 68 - 69. BASEL: KARGER. ISSN 2296-5262

Stegelmann, F., Hebart, H., Bangerter, M., Wolleschak, D., Griesshammer, M., Koschmieder, S., Hochhaus, A., Heidel, F., Moehle, R., Reiter, A., Scheid, C., von Bubnoff, N., Kirschbaum, R., Reim, R., Sutter, U., Vetter, K., Doehner, H., Schlenk, R. F. and Doehner, K. (2016). Ruxolitinib/Pomalidomide combination therapy in myelofibrosis: Current data from the MPNSG-0212 trial. Oncol. Res. Treat., 39. S. 233 - 235. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Iltgen, J., Wennhold, K., Marquez, M. Garcia, Rothschild, S., Schneider, B., Holtick, U., Thelen, M., Scheid, C., Becker, Hj, Schloesser, H., Reuter, S., Vornhagen, A. Shimabukuro and von Bergwelt-Baildon, M. (2016). THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL. Haematologica, 101. S. 462 - 463. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2015

Baertsch, M., Wuchter, P., Schlenzka, J., Weisel, K., Noppeney, R., Martin, H., Lindemann, H., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I., Klein, S., Ho, A. and Goldschmidt, H. (2015). EFFICIENCY AND TOXICITY OF CYCLOPHOSPHAMIDE BASED STEM CELL MOBILIZATION IN RELAPSED MULTIPLE MYELOMA PATIENTS: OBSERVATIONS FROM THE ONGOING PHASE III TRIAL RELAPSE. Haematologica, 100. S. 258 - 260. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Chakupurakal, G., Garcia-Marquez, M., Shimabukuro vorn-hagen, A., Schloesser, H., Holtick, U., Scheid, C. and von Bergwelt-Baildon, M. (2015). Changes in T and B- cells in steroid refractory GvHD patients following treatment with a CD25-antibody. Bone Marrow Transplant., 50. S. S177 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Chakupurakal, G., Garcia-Marquez, M., Shimabukuro-Vorn-hagen, A., Theurichi, S., Scheid, C., Hallek, M., Holtick, U. and von Bergwelt-Baildon, M. (2015). IL-10 producing B-10 cells can be identified as early as 30 days post an allogeneic stem cell transplant and are enriched in the transitional B-cell compartment. Bone Marrow Transplant., 50. S. S176 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584

Einsele, H., Vogel, M., Mueller, J., Knop, S., Kropff, M., Langer, C., Sayer, H., Jung, W., Wandt, H., Bassermann, F., Gramatzki, M., Roesler, W., Brugger, W., Engelhardt, M., Fischer, T., Giagounidis, A., Heidemann, E., Kroeger, N., Sezer, O., Bentz, M., Pfreundschuh, M., Salwender, H., Ludwig, W. -D., Roellig, C., Staib, P., Runde, V., Scheid, C., Ostermann, H., Hess, G., Hebart, H., Repp, R., Hart, C., Frickhofen, N., Straka, C. and Pflueger, K. -H. (2015). RESULTS FROM TWO PHASE 3 STUDIES OF POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). Haematologica, 100. S. 151 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Engel, L. A., Wittig, S., Bock, F., Sauerbier, L., Scheid, C., Holtick, U., Chemnitz, J-M, Hallek, M., Cursiefen, C. and Steven, P. (2015). Meibography and meibomian gland measurements in ocular graft-versus-host disease. Bone Marrow Transplant., 50 (7). S. 961 - 968. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Heidenreich, S., Zabelina, T., van Biezen, A., Finke, J., Platzbecker, U., Niederwieser, D., Einsele, H., Bethge, W., Schwerdtfeger, R., Beelen, D., Tischer, J., Nagler, A., Zachee, P., Scheid, C., de Witte, T., Robin, M. and Kroger, N. (2015). Allogeneic stem cell transplantation for MDS patients more than 70 years of age. A report of MDS subcommittee of CMWP of EBMT. Bone Marrow Transplant., 50. S. S305 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Mai, E. K., Benner, A., Bertsch, U., Schmidt-Wolf, I. G. H., Haenel, A., Kunzmann, V, Naumann, R., Neben, K., Egerer, G., Hillengass, J., Neubauer, A., Peyn, A., Ko, Y-D, Peter, N., Salwender, H. J., Scheid, C. and Goldschmidt, H. (2015). Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in newly-diagnosed multiple myeloma: final results from the GMMG-HD2 trial. Oncol. Res. Treat., 38. S. 9 - 11. BASEL: KARGER. ISSN 2296-5262

Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2015). Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 29 (8). S. 1721 - 1730. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Scheid, C., Blommer, J., Holtick, U., Chemnitz, J., Malchau, G., Streichert, T. and Hallek, M. (2015). Using IgM hevylite to distinguish MGUS from malignant disorders with clonal IgM Paraprotein. Oncol. Res. Treat., 38. S. 239 - 240. BASEL: KARGER. ISSN 2296-5262

Scheid, C., Holtick, U., Bornhaeuser, M., Kroeger, N., Ganser, A., Arnold, R., Dreger, P., Stuhler, G., Theobald, M., Peschel, C., Hallek, M., Niederwieser, D., Finke, J., Hertenstein, B. and Beelen, D. (2015). Effects of Busulfan dose and administration route on transplantation outcome in adult patients with AML or MDS - a retrospective analysis of the German transplant registry DRST. Bone Marrow Transplant., 50. S. S224 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M. and Goldschmidt, H. (2015). Comparative assessment of myeloma response to induction treatment in the GMMG MM5 study using IMWG criteria and hevylite assay. Oncol. Res. Treat., 38. S. 10 - 11. BASEL: KARGER. ISSN 2296-5262

Stegelmann, F., Bangerter, M., Griesshammer, M., Hebart, H., Heidel, F., Hochhaus, A., Moehle, R., Reiter, A., Scheid, C., Kirschbaum, R., Reim, R., Sutter, U., Doehner, H., Schlenk, R. F. and Doehner, K. (2015). A phase-Ib/II study of ruxolitinib plus pomalidomide in Myelofibrosis: Data from the MPNSG-0212 Trial (NCT01644110). Oncol. Res. Treat., 38. S. 216 - 218. BASEL: KARGER. ISSN 2296-5262

Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, Sicre F., Na, I. -K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Grigoleit, G. U., Kuball, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis of 95 patients treated at multiple medical centers. Oncol. Res. Treat., 38. S. 43 - 45. BASEL: KARGER. ISSN 2296-5262

Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 29 (10). S. 2062 - 2069. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

2014

Holtick, U., Frenzel, L., Froehlich, H., Shimabukuro-Vornhagen, A., Theurich, S., Claasen, J., Scheid, C., von Bergwelt-Baildon, M., Wendtner, C. and Chemnitz, J. (2014). INCREASED FUNCTIONAL T CELL DEFECTS IN PATIENTS WITH LOW CD4 COUNTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Bone Marrow Transplant., 49. S. S558 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Koenecke, C., Goehring, G., de Wreede, L., van Biezen, A., Scheid, C., Volin, L., Maertens, J., Finke, J., Schaap, N. P. M., Robin, M., Passweg, J., Cornelissen, J., Beelen, D., Heuser, M., de Witte, T. and Kroeger, N. (2014). IMPACT OF CYTOGENETIC USING THE IPSS REVISED CYTOGENETIC CLASSIFICATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS OR AML EVOLVING FROM MDS: A RETROSPECTIVE MULTICENTER STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT. Bone Marrow Transplant., 49. S. S8 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Kron, F., Glossmann, J. P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., von Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K. -A., Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Hallek, M. and Wolf, J. (2014). A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany. Oncol. Res. Treat., 37. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262

Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2014). Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5. Oncol. Res. Treat., 37. S. 150 - 152. BASEL: KARGER. ISSN 2296-5262

Scheid, C., de Wreede, L., van Biezen, A., Goehring, G., Koenecke, C., Volin, L., Maertens, J., Finke, J., Schaap, N., Socie, G., Passweg, J., Cornelissen, J., Beelen, D., de Witte, T. and Kroeger, N. (2014). THE REVISED IPSS (IPSS-R) AT TRANSPLANT PREDICTS OVERALL AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MDS/SAML: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY. Bone Marrow Transplant., 49. S. S93 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Schmidt-Wolf, I. G. H., Straka, C., Scheid, C., Einsele, H., Goldschmidt, H. and Engelhardt, M. (2014). State of the art treatment of progressive or refractory multiple myeloma. Dtsch. Med. Wochenschr., 139 (41). S. 2091 - 2096. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Vitinius, F., Scherer, S., Scheid, C., Von Bergwelt-Baildon, M., Romuender, M., Hein-Nau, B. and Albus, C. (2014). Psychosocial strain and adherence in allogeneic hematopoietic stem cell transplantation (HSCT) - Cross-sectional data from a prospective study. J. Psychosomat. Res., 76 (6). S. 517 - 519. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1879-1360

Xhaard, A., Rzepecki, P., Valcarcel, D., Santarone, S., Fuerst, S., Serrano, D., De Angelis, G., Krueger, W. and Scheid, C. (2014). Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients. Bone Marrow Transplant., 49 (4). S. 509 - 513. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

von Bergwelt-Baildon, M., Holtick, U., Hallek, M. J. and Scheid, C. (2014). Hematopoietic stem cell transplantation. Bone marrow and blood stem cells. Internist, 55 (11). S. 1306 - 1313. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

2011

Schlaak, M., Kurschat, P., Shimabukuro-Vornhagen, A., Scheid, C., Chemnitz, J., Stadler, R., von Bergwelt-Baildon, M. and Theurich, S. (2011). Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl. Immunol., 25 (2-3). S. 163 - 167. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 0966-3274

This list was generated on Tue Nov 26 06:15:26 2024 CET.

Export as	Atom RSS 1.0 RSS 2.0